Tag Archives: CHMP of the European Medicines Agency

Novartis: CHMP of the European Medicines Agency adopted a positive opinion for Jakavi® (ruxolitinib) for the treatment of adult patients with polycythemia vera

Posted on 26, January 2015 by

Polycythemia vera (PV) is associated with overproduction of blood cells that can cause serious cardiovascular complications, such as stroke and heart attack[1] Clinical data show Jakavi® (ruxolitinib) significantly improved hematocrit levels and reduced spleen size, key measures of disease control[2] … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Switzerland

Tagged , , , , ,